IL-17, IL-23 and IL-12/23 biologics on HealthSpring Extra Rx (S5617-367)
Stelara and its biosimilars, Skyrizi, Tremfya, Cosentyx and Taltz, for psoriasis, psoriatic arthritis and Crohn's, checked against this plan's 2026 formulary (its list of covered drugs).
- Plan type
- Stand-alone drug plan (PDP), Illinois
- Premium
- $66.60/month
- Deductible
- $615.00, doesn't apply to tier 1 and 2
6 of 9 IL-17 and IL-23 biologics are covered on this plan. All 6 require prior authorization.
3 aren't on the formulary, including Wezlana and Taltz.
- from $1,212.25Tier 5
- from $1,212.25Tier 5
- from $365.21Tier 3
- from $2,229.45Tier 5
- from $3,642.30Tier 5
- from $5,833.54Tier 5
Not on the formulary
Wezlana, Taltz, Bimzelx
Patient cost for a 30-day supply at a preferred retail pharmacy, after the $615.00 deductible where it applies. Where the plan charges a percentage (coinsurance), the dollar figure is that share of the plan's negotiated price; "from" means other strengths cost more. Data from the CMS 2026 Part D formulary and pricing files.